Latest news
Loading news…
Cullinan Pearl
ClosedOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring). Cambridge, Massachusetts, United States Founded 2016 1-10 employees For Profit
Cullinan Pearl develops an orally available tyrosine kinase inhibitor to target Epidermal Growth Factor Receptor exon 20 mutations.
Cullinan Pearl was acquired by Taiho Pharmaceutical in 2022 for $275M.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
6
Patents
1
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Patents granted
- 1
- Trademarks
- 0
- Top patent class
- a61
- IT spend
- $9M
Company Info
- Founded
- 2016
- Employees
- 1-10
- Operating status
- Closed
- Company type
- For Profit
- Org types
- company
- HQ
- Cambridge, Massachusetts, United States
- Region
- Greater Boston Area, East Coast, New England
- Exit date
- May 12, 2022
Signals & Scores
- Heat score
- Low
- Trend (7d)
- 0
- Trend (30d)
- -0.3
- Trend (90d)
- -0.5
6
professional contacts at Cullinan Pearl
Contact execs at Cullinan Pearl →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Cullinan Pearl
Loading news…
FAQs about Cullinan Pearl
People who checked this page also checked these
Browse the full Acquirezy directory.